Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance of [14C]-AT-527 in healthy males
NCT05004415Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) and hepatitis C (HCV), sponsored by Atea Pharmaceuticals. Primary endpoint: Mass Balance. Started Jul 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05004415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004415.